DS 9001

Drug Profile

DS 9001

Alternative Names: DS-9001

Latest Information Update: 22 Mar 2016

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antihyperlipidaemics; Proteins
  • Mechanism of Action Immunomodulators; PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dyslipidaemias

Most Recent Events

  • 01 Dec 2015 Phase-I clinical trials in Dyslipidaemias (unspecified route)
  • 23 Nov 2015 Preclinical trials in Undefined indication in Japan (unspecified route) before November 2015
  • 25 Jun 2013 Daiichi Sankyo Company and Affibody enter into a license agreement for the Albumod™ platform
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top